TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
WGS

GeneDx Holdings Corp.

Healthcare · Diagnostics & Research

97.80$ -3.2% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Income Statement

GeneDx Holdings Corp. (WGS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 114 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement WGS
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
53 57 62 71 77 96 87 103 117 121 102 114 454
28 27 25 28 29 29 29 32 32 42 34 36 145
25 31 37 43 48 66 58 71 85 79 68 78 310
14 12 12 11 12 12 13 15 20 24 20 20 83
26 27 23 26 26 27 32 27 44 47 75 73 238
68 56 51 54 56 57 63 62 88 93 94 96 371
-43 -26 -14 -11 -7.8 8.8 -4.6 9.0 -3.3 -14 -26 -17 -61
1.0 0.6 0.9 0.8 0.7 0.6 0.8 0.6 0.5 0.7 1.2 3.0
-42 -26 -20 -29 -8.4 5.4 -6.1 11 -7.4 -18 -62 -18 -106
-0.2 -0.4 -0.1 -0.2 0.0 0.0 0.4 -0.2 0.2 -0.6 0.9 0.5 1.1
-42 -26 -20 -29 -8.3 5.4 -6.5 11 -7.6 -18 -63 -18 -106
-26 -19 -14 -23 -1.6 12 0.2 18 -0.4 -11 -55 -10 -76

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?